Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Research & Development is the aggregate amount of research and development expenses during the year. Asston Pharmaceuticals's Research & Development for the
six
months ended in Mar. 2026 was ₹0.0 Mil.
Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil.
Asston Pharmaceuticals (BOM:544445) Research & Development Explanation
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Asston Pharmaceuticals Research & Development Related Terms
Asston Pharmaceuticals Research & Development Historical Data
* Premium members only.
The historical data trend for Asston Pharmaceuticals's Research & Development can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asston Pharmaceuticals Research & Development Chart
Asston Pharmaceuticals Research & Development Calculation
This is the expense the company spent on research and development.
Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Research & Development of ₹0.0 Mil mean?
Asston Pharmaceuticals (BOM:544445) has a Research & Development of ₹0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Asston Pharmaceuticals and its competitors.
Is Asston Pharmaceuticals' Research & Development too high?
Asston Pharmaceuticals' current Research & Development is ₹0.0 Mil. Overall, Asston Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Asston Pharmaceuticals' Research & Development compare to ZTS?
Asston Pharmaceuticals' Research & Development of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Asston Pharmaceuticals and its competitors. Asston Pharmaceuticals's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asston Pharmaceuticals stock overvalued right now?
Asston Pharmaceuticals (BOM:544445) has a current Research & Development of ₹0.0 Mil. The current Research & Development is ₹0.0 Mil. Asston Pharmaceuticals' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Asston Pharmaceuticals (BOM:544445), the current Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asston Pharmaceuticals Ltd manufactures and exports pharmaceutical and nutraceutical products. The company produces a wide range of healthcare items including tablets, capsules, syrups, sachets, ointments, creams, gels, and lotions. It serves markets in West and South Africa, with expansions planned into Asian countries. Asston conducts business through export sales, contract manufacturing and loan license arrangements via merchant exporters, and domestic sales within India. Revenue is generated through the sale of branded and generic pharmaceutical formulations along with nutraceutical products. The business operations are broadly categorized into: Domestic Formulations, Export Formulations, APIs and Intermediates, and Research and Development.
19GF Score
Get the complete analysis for BOM:544445
Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544445 has been successfully added to your 
